The Role of ADRB2 in Myasthenia: Genetic and Immunological Factors.

Lantsova, V.; Gerasimov, A.; Sepp, E.

To examine the possibility of using ADRB2 adrenergic receptor agonists for correction of myasthenia-induced immunological and motor disturbances, a method of anti-ADRB2 antibody assay by ELISA was developed. The haplotype of ADRB2 gene was determined by MLPA-PCR in 34 myasthenia patients; blood sera from 40 patients were examined. The content of antibodies against ADRB2 receptors was elevated in 12 of 30 patients with generalized form of myasthenia. Arg-Arg in position 16 in ADRB2 receptors determines the developmental risk of side effects, while Gly-Gly in the same codon determines tolerance to β-adrenoceptor agonists and is associated with more severe course of myasthenia and resistance to β-adrenoceptor agonists treatment with ADRB2 agonists. The study demonstrated the possibility of using ADRB2 obtained gene engineering technique for quantitatively assay the autoantibodies.

ADRENERGIC receptors; MUSCLE weakness; GENETIC polymorphisms; IMMUNOGLOBULINS; ENZYME-linked immunosorbent assay; GENETIC engineering

Bulletin of Experimental Biology & Medicine, 2013, Vol 154, Issue 3, p351

0007-4888

Academic Journal

10.1007/s10517-013-1948-0